IL23A and neoplasm: As also showed by Calcinotto et al. [86] in several murine models of PCa, including the phosphatase and tensin homolog (PTEN) conditional knockout (KO) and TRAMP-C1 mouse models, PMN-MDSCs can activate the AR pathway by IL-23 release and favor tumor cell proliferation even after androgen inhibition.